Pacesetter, Inc.

St. Jude Medical, Cardiology Division, Inc.

Martin Cholette

Gene A Bornzin

Xiaoyi Min

John W Poore

Eric Steven Fain

Gary R Dulak

J Christopher Moulder

Yong D Zhao

Lanitia Ness

Stuart Rosenberg

Kyungmoo Ryu

Phong D Doan

Kevin L Morgan

Rolf Hill

Sean Matthew Desmond

Ingmar Viohl

Gregory Hauck

Ruth Lyons

Sergio Shkurovich

Nabil A Mouchawar

Catherine Tan

A renal denervation feedback method is described that performs a baseline measurement of renal nerve plexus electrical activity at a renal vessel; denervates at least some tissue proximate the renal vessel after performing the baseline measurement; performs a post-denervation measurement of renal nerve plexus electrical activity at the renal vessel, after the denervating; and assesses denervation of the renal vessel based on a comparison of the baseline measurement and the post-denervation measurement of renal nerve plexus electrical activity at the renal vessel.

System and method for performing renal denervation verification

A renal denervation catheter includes a catheter shaft, at least one ablation member, and a sensor, and is operable to perform a renal denervation procedure. The catheter shaft includes a distal end portion insertable into a renal artery. The at least one ablation member is positioned at the distal end portion of the catheter shaft and operable to ablate renal nerves along a wall of the renal artery. The sensor provides information that correlates to blood flow in the renal artery. A change in blood flow rate in the renal artery resulting from the ablation is indicative of the efficacy of the renal denervation procedure.

Quantification of renal denervation via alterations in renal blood flow pre/post ablation

The present disclosure provides neurostimulation systems and methods. A neurostimulation system includes at least one anode, at least one cathode, the at least one anode and the at least one cathode configured to apply electrical stimulation to a patient, and a controller electrically coupled to the at least one anode and the at least one cathode, the controller configured to determine when one of the at least one anode and the at least one cathode fails, measure, in response to the determination, a quantity indicative of a charge density of the applied electrical stimulation, compare the measured quantity to a predetermined limit, and perform at least one action when the measured quantity exceeds the predetermined limit.

Systems and methods for monitoring charge density of electrical stimulation

An exemplary method for treating obesity includes an pulse generator configured to deliver electrical energy to a vagal nerve, one or more sensors configured to detect pre-prandial activity and, in response to the detection of pre-prandial activity, a pulse generator configured to deliver electrical energy to the stomach to induce satiety. Various other technologies are also disclosed.

Detection of feeding intent for use in treatment of eating disorders

Techniques are provided for controlling and delivering spinal cord stimulation (SCS) or other forms of neurostimulation. In one example, neurostimulation pulses are generated wherein successive pulses alternate in polarity so that a pair of electrodes alternate as cathodes. Each pulse has a cathodic amplitude sufficient to achieve cathodic capture of tissues adjacent the particular electrode used as the cathode for the pulse. The neurostimulation pulses are delivered to patient tissues using the electrodes to alternatingly capture tissues adjacent opposing electrodes via cathodic capture to achieve a distributed virtual stimulation cathode. Various pulse energy savings techniques are also set forth that exploit the distributed virtual stimulation cathode.

Systems and methods for providing a distributed virtual stimulation cathode for use with an implantable neurostimulation system

Systems and methods are provided wherein intracardiac electrogram (IEGM) signals are used to determine a set of preliminary optimized atrioventricular (AV/PV) and interventricular (VV) pacing delays. In one example, the preliminary optimized AV/VV pacing delays are used as a starting point for further optimization based on impedance signals such as impedance signals detected between a superior vena cava (SVC) coil electrode and a device housing electrode, which are influenced by changes in stroke volume within the patient. Ventricular pacing is thereafter delivered using the AV/VV pacing delays optimized via impedance. In another example, parameters derived from IEGM signals are used to limit the scope of an impedance-based optimization search to reduce the number of pacing tests needed during impedance-based optimization. Biventricular and multi-site left ventricular (MSLV) examples are described.

Systems and methods for optimizing AV/VV pacing delays using combined IEGM/impedance-based techniques for use with implantable medical devices

A set of cardiogenic impedance signals are detected along different sensing vectors passing through the heart of the patient, particularly vectors passing through the ventricular myocardium. A measure of mechanical dyssynchrony is detected based on differences, if any, among the cardiogenic impedance signals detected along the different vectors. In particular, differences in peak magnitude delay times, peak velocity delay times, peak magnitudes, and waveform integrals of the cardiogenic impedance signals are quantified and compared to detect abnormally contracting segments, if any, within the heart of the patient. Warnings are generated upon detection of any significant increase in mechanical dyssynchrony. Diagnostic information is recorded for clinical review. Pacing therapies such as cardiac resynchronization therapy (CRT) can be activated or controlled in response to mechanical dyssynchrony to improve the hemodynamic output of the heart.

System and method for evaluating mechanical cardiac dyssynchrony based on multiple impedance vectors using an implantable medical device

Stimulation of a patient's nervous system is controlled based on cardiovascular risk assessment performed by an implantable medical device. For example, an implantable medical device may monitor cardiac electrical activity to detect changes in the ST segment. Upon detection of a certain change in the ST segment, the implantable medical device controls the application of spinal cord stimulation and/or other neurostimulation to cardiac-related sections of the patient's nervous system. In some embodiments, the implantable medical device communicates with a separate neurostimulation device to control the neurostimulation. In some embodiments, the implantable medical device delivers the neurostimulation.

Neurostimulation controlled by assessment of cardiovascular risk

The invention is directed towards measuring current of injury (COI) during lead fixation. A baseline waveform is sensed from a lead while the lead is in a pre-fixation position. The baseline waveform represents an interface between the lead and tissue proximate a lead prior to active fixation. Cardiac signals are then sensed when the lead is in a post-fixation position. The post-fixation waveform represents an interface between the lead and the tissue once the lead is actively attached to the tissue. A COI is calculated based on an automatic comparison of the baseline and post-fixation waveforms. A COI feature of interest is identified in the baseline and post-fixation waveforms and a COI index, a COI area, a COI differential and/or a COI ratio is calculated based on the COI feature of interest in the baseline and post-fixation waveforms.

Method and system for quantitative measure of current of injury during lead fixation

A lead assembly of an implantable medical device includes an elongated body, electrodes on the body, and a tracking sensor located in the body. The body extends between a connector end and a leading end and has conductors disposed in the body. The connector end of the body includes terminals coupled with the conductors. The electrodes disposed on the body can be located at or near an anatomy of interest in a patient and are conductively coupled with the terminals of the body by the conductors. The electrodes are configured to sense electric activity of the anatomy of interest and/or deliver stimulus pulses to the anatomy of interest. The tracking sensor is conductively coupled with the terminals of the body by the conductors. The tracking sensor generates an electric position signal representative of a position of the tracking sensor in the heart when the body is in the patient.

Implantable lead assembly having a position tracking sensor and method of manufacturing the lead assembly

An implantable lead is provided that includes a lead body configured to be implanted in a patient. The lead body has a distal end and a proximal end, and a lumen extending between the distal and proximal ends and includes a connector assembly provided at the proximal end of the lead body. The connector assembly is configured to connect to an implantable medical device and includes an electrode provided proximate to the distal end of the lead body with the electrode configured to at least one of deliver stimulating pulses and sense electrical activity. A multi-layer coil is located within the lumen and extends at least partially along a length of the lead body. The coil includes a first winding formed with multiple winding turns, the winding turns being segmented in an alternating pattern of insulated segments and non-insulated segments along the length of the lead body. The multi-layer coil further includes a winding turn connective layer extending along and interconnecting the winding turns within at least one of the non-insulated segments. The multi-layer coil further includes a first winding formed with multiple winding turns, the winding turns being segmented into an alternating pattern of insulated segments and non-insulated segments along a length of the winding with a winding turn connective layer extending along and interconnecting the winding turns within at least one of the non-insulated segments.

MRI compatible implantable lead

An exemplary method for treating an eating or metabolism disorder includes calling for delivery of energy to the stomach using a pulse train that includes use of pulses with a pulse width less than approximately 20 ms, a duty cycle greater than approximately 20% and a pulse train duration of less than approximately 10 seconds and calling for delivery of energy to a vagal nerve. Various other methods, devices, systems, etc., are also disclosed.

Dual therapy electrical stimulation system for treating metabolic and eating disorders

An exemplary method for treating obesity includes calling for delivery of electrical energy to a vagal nerve, detecting pre-prandial activity and, in response to the detection of pre-prandial activity, calling for delivery of electrical energy to the stomach for a pre-determined amount of time to induce satiety. Various other technologies are also disclosed.

Growing community of inventors

Acton, CA, United States of America

Martin Cholette